Shots:

• The P-III study involves assessing Covaxin (COVID-19 vaccine candidate) vs PBO in 25-798 patients aged 18-98 yrs include 2-750 >60 yrs. of age & 7-065 with comorbidities in over 25 centers across India and is being conducted in partnership with ICMR & NIV
• The results from the P-III study demonstrates overall efficacy of 77.8% with 93.4% protective against severe COVID-19 alone while efficacy data demonstrates 65.2% protection against B.1.617.2 (delta) & B.1.351 (beta) variant
• The company will submit BLA for Covaxin in the US & initiates the discussions with Health Canada for regulatory approval while Covaxin is currently being administered under EUA in 13 countries

  | Ref: Globe Newswire | Image: Crunchbase